# **CASE REPORT**

## **Open Access**



# An unusual presentation of fucosidosis in a Chinese boy: a case report and literature review (childhood fucosidosis)

Shao-Jia Mao<sup>1</sup>, Jia Zhao<sup>1,2</sup>, Zheng Shen<sup>1</sup> and Chao-Chun Zou<sup>1\*</sup>

### Abstract

**Background:** Fucosidosis is one of the rare autosomal recessive lysosomal storage diseases (LSDs) attributed to FUCA1 variants causing the deficiency of  $\alpha$ -L-fucosidase in vivo. A-L-fucosidase deficiency will cause excessive accumulation of fucosylated glycoproteins and glycolipids, which eventually leads to dysfunction in all tissue systems and presents with multiple symptoms. Fucosidosis is a rare disease which is approximately 120 cases have been reported worldwide (Wang, L. et al., J Int Med Res 48, 1-6, 2020). The number of reported cases in China is no more than 10 (Zhang, X. et al., J Int Med Res 49:3000605211005975, 2021).

**Case presentation:** The patient was an 8-year-old Chinese boy who presented with postnatal motor retardation, intellectual disability, short stature, language development retardation, coarse facial features, hepatomegaly, and diffuse angiokeratoma of both palms. His genetic testing showed the presence of a homozygous pathogenic variant (c.671delC) in the FUCA1 gene. In addition, the enzymatic activity of  $\alpha$ -L-fucosidase was low. Ultimately, the patient was diagnosed with fucosidosis.

**Conclusions:** Fucosidosis is a rare lysosomal storage disease because of FUCA1 variants that cause the deficiency of α-L-fucosidase in vivo. An explicit diagnosis requires a combination of clinical manifestations, imaging examination, genetic testing and enzyme activity analysis. Early diagnosis plays an important role in fucosidosis.

Keywords: Fucosidosis, Lysosomal storage disease, a-L-fucosidase, All tissue systems, FUCA1

#### Background

Fucosidosis (OMIM 230,000) is one of the autosomal recessive lysosomal storage diseases (LSDs) caused by variants of FUCA1 (NG\_013346) on chromosome 1p36.11 [1]. The FUCA1 gene encodes  $\alpha$ -L-fucosidase (EC 3.2.1.51). Fucosidosis is a rare disease which is about 120 cases have been reported worldwide. A-L-fucosidase is a lysosomal enzyme that degrades fucosylated glycoproteins and glycolipids in vivo. The deficiency of

\*Correspondence: zcc14@zju.edu.cn

 $\alpha$ -L-fucosidase leads to the excessive accumulation of fucosylated glycoproteins and glycolipids in multiple tissues and organs, such as brain, bone, skin, and liver, causing multiple clinical symptoms. Most patients have intellectual disability, dyskinesia, coarse facial features, recurrent respiratory infections, growth retardation, and dysostosis multiplex [2]. These symptoms are similar to those of other LSDs, such as mucopolysaccharidosis (MPS) and mucolipidosis (ML). In addition, some patients have diffuse telangiectasia or angiokeratomas which has been observed more often in older patients [1, 3, 4]. Moreover, other symptoms, such as hepatosplenomegaly, epilepsy, and inguinal hernia, are often manifested in patients with fucosidosis. According to onset age and clinical features, fucosidosis is divided into two



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicate of therwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedicated in a credit line to the data.

<sup>&</sup>lt;sup>1</sup> Department of Endocrinology, the Children's Hospital of Zhejiang University School of Medicine, No 3333 Binsheng Road, Hangzhou 310051, Zhejiang Province, China

Full list of author information is available at the end of the article

types. Type I usually begins early (before the age of one year) and progresses relatively quickly. In addition, the deterioration of the nervous system is faster than that of type II. Typical patients of Type I tend to die between the ages of 5 to 10. Type II often begins later than 2 years old, progresses more slowly, and usually allows patients to survive until adulthood [1, 5]. However, because fucosidosis is extremely rare and has nonspecific clinical manifestations, the diagnosis of these patients is often delayed. Herein, we reported an 8-year-old Chinese boy with fucosidosis who was previously misdiagnosed with MPS.

#### **Case presentation**

An 8-year-old boy visited our unit for "motor and intellectual retardation". He was G1P1 (first pregnancy & first delivery) of non-consanguineous healthy parents and was delivered naturally at term with a birth weight of 3.25 kg (-0.39 SD). The movement retardation was noted after birth. He was not able to walk until the age of 18 months. Up to now, he continued to walk unsteadily and unsymmetrically. Moreover, he could only unconsciously utter the word "mother", and his intellectual disability prevented conscious communication. The growth retardation also was noted that the growth rate was only 2 cm per year in recent years. Since the age of 3 years, there have been dense red rashes on the palms of both hands. The rashes spread from hand to trunk. The patient used to suffer from recurrent respiratory infections. He had a right inguinal hernia at 5 years old and then underwent high ligation of the hernia sac under the laparoscope in the same year. No similar genetic family history was reported.

Physical examination showed a height of 116.5 cm (-2.48 SD) and a weight of 25 kg (-0.60 SD). The ability to communicate was missing. He had dull eyes, slightly coarse facial features, black hair, and thick eyebrow. The liver was relatively enlarged and about 3 cm under the ribs. The spleen was not palped under the ribs. Muscular hypotonia was noted. Each finger couldn't be fully extended (Fig. 1A). Numerous red rashes were seen on both palms (Fig. 1B). Cardiopulmonary auscultation showed no abnormality. The muscle strength of the limbs was normal. Eye manifestations were undetected. No other obvious abnormality was found.

The hepatosplenic ultrasound showed hepatomegaly with the length of 4.5 cm under the ribs. Echocardiography indicated mild tricuspid regurgitation without valve thickening or myocardial hypertrophy. X-ray of the spine revealed the presence of physiological curvature of the spine, tapering of the anterior vertebral body with irregular morphology, and local bone hyperplasia of the vertebral body. The proximal end of the ribs was concave. Each acetabulum was shallow, and its margin was irregular (Fig. 2A-C). In the brain Magnetic Resonance Imaging(MRI), the globus pallidus showed symmetrical hyperintensity on T1-weighted images and symmetrical hypointensity on T2-weighted images with a linear high-intensity zone in the middle. The volume of cerebral white matter was decreased slightly. Liver and kidney function, blood gas, electrolyte, blood glucose, thyroid function, and the genetic metabolic indexes of peripheral blood were all normal.


MPS was initially suspected. Urinary glycosaminoglycans (GAGs) screen for MPS was performed by dimethylmethylene blue dye binding assay with the boundary result. Hence, other genetic diseases (e.g., myxolipomatosis or fucosidosis) were considered. Whole exon sequencing performed for the boy and his parents showed a presence of a homozygous pathogenic variant (c.671delC in exon 4) of FUCA1 gene, inherited from his parents (Fig. 3A-C). The c.671delC is a de novo and frameshift pathogenic variant that causes a premature stop codon (p.Pro224LeufsTer3). This variant was not reported previously in GnomAD data and was regarded as pathogenic according to the ACMG criterion. In order to make sure, the  $\alpha$ -L-fucosidase activity analysis was done that the level of  $\alpha$ -L-fucosidase in white blood cells was 0.08 nmol/h.mg (normal range 31.44-104.84). The patient was eventually diagnosed with fucosidosis.


#### **Discussion and conclusions**


Fucosidosis is an extremely rare disease. To our knowledge, this is the seventh case reported from China [2, 6]. Its clinical features were similar to those of some LSDs, such as MPS and ML. According to the literature, about 95% showed intellectual disability, 87% presented with movement disorders, 78% had coarse facial features, 78% had recurrent respiratory infections, 78% had growth retardation, 58% had dysostosis multiplex, 52%



Fig. 1 Clinical manifestations of the patient. A Palms with a dense red rash; (B) Fingers that couldn't be fully extended







had diffuse telangiectasia or angiokeratoma on the skin which showed an obvious increase in incidence with age, 44% showed liver and spleen enlargement, and 38% had epilepsy [7]. Other clinical symptoms, including inguinal hernia, dystonia, visual impairment and corneal opacity, were also reported [1]. Our patient presented with intellectual disability, movement disorder, light coarse facial features, recurrent respiratory infections, growth retardation, dysostosis multiplex, diffuse angiokeratoma on the skin, hepatomegaly, dystonia, and inguinal hernia. These symptoms were consistent with clinical features in previous studies. For patients presenting with these above symptoms, fucosidosis should be considered except for MPS.

Imaging examination plays an important auxiliary role in the diagnosis. In the vast majority of case reports, the brain MRI shows symmetrical hyperintensity of the globus pallidus on T1-weighted images and symmetrical hypointensity of the globus pallidus with a linear highintensity zone in the middle separating its medial and lateral segments on T2-weighted images. There are diffuse symmetric high signal zones in bilateral subcortical and deep white matter on T2-weighted images. Low signal of the thalami on T2-weighted is an important sign which prompts LSDs [8–11]. Early in the disease, cranial Computed Tomography (CT) shows increased cerebellar volume. In the late stages, cranial CT demonstrates diffuse atrophy both in cerebrum and cerebellum [1, 12]. In X-ray, patients of fucosidosis often present with dysostosis multiplex, such as anterior beaking of thoracolumbar vertebrae, lumbar hyperlordosis, kyphosis, scoliosis, small fifth lumbar vertebrae, short odontoid, widened and sclerotic long bone diaphysis, widened and scalloped acetabular roof. In addition, the skull will be thickened, and paranasal sinuses will be absent or hypoplastic. In summary, fucosidosis often show bone deformity and destruction in X-ray [12].

Fucosidosis should be suspected when patients present with the above clinical manifestations, imaging characteristics, and negative results of urinary GAGs. Moreover, enzyme activity detection suggesting low activity of  $\alpha$ -L-fucosidase is the gold standard for diagnosis. Unfortunately, enzyme activity detection is not available in most hospitals in China. By comparison, high-throughput sequencing is more accessible in China and plays an important role in the diagnosis. Through the combined analysis of the clinical manifestations, typical MRI and X-ray findings, low activity of  $\alpha$ -L-fucosidase and a homozygous frameshift variant of FUCA1 gene, our patient was finally diagnosed with fucosidosis at 7 years old.

Treatment means for this disease are given priority to symptomatic treatment currently. According to relevant literature, hematopoietic stem cell transplantation has been used in a few cases with the results of a significant increase in  $\alpha$ -L-fucosidase activity and the improvement of partial clinical symptoms after earlier transplantation. But the long-term effects and complications of this treatment are undefined [13, 14]. The critical treatment for other LSDs like MPS is enzyme replacement therapy which is an undergoing preclinical study for fucosidosis [14, 15]. Gene therapy is also one of the key research directions in the future.

We report a case of fucosidosis which is caused by a homozygous pathogenic variant in the FUCA1 gene. Combined with enzyme activity detection and genetic testing, we got a definite diagnosis. In summary, when patients with similar clinical manifestations, brain MRI revealed symmetrical hypointensity of the globus pallidus with a linear high-intensity zone in the middle on T2-weighted images, and negative results of urinary GAGs, fucosidosis needs to be suspected. Genetic testing and/or enzyme activity detection help to make a definite diagnosis.

#### Abbreviations

LSDs: Lysosomal storage diseases; MPS: Mucopolysaccharidosis; ML: Mucolipidosis; GAGs: Glycosaminoglycans; MRI: Magnetic Resonance Imaging; CT: Computed Tomography.

#### Acknowledgements

We are very grateful to the patient and his parents for allowing us to use the data. We express our sincere thanks to Bob for English language editing.

#### Authors' contributions

SJ Mao, JZ, and ZS collected data and drafted the manuscript. CC Zou developed the research plan and revised the manuscript. The author(s) read and approved the final manuscript.

#### Funding

This study was supported by the Key R & D Projects of Zhejiang Provincial Department of Science and Technology (2021C03094), National Natural Science Foundation (81371215 & 81670786), and Zhejiang Medical and Health Scientific Research Fund (2016KYA127). The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

#### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

#### Declarations

#### Ethics approval and consent to participate

The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board (or Ethics Committee) of Medical ethics committee of The Children's Hospital Affiliated to Medical College of Zhejiang University (protocol code: 2021-IRB-085 and date of approval: 2021.04.12). The patient's parents provided written consent to participate in genetic screening.

#### **Consent for publication**

Written consent to publish this information has been obtained from the guardian for the study participant under 18 years old.

#### **Competing interests**

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

#### Author details

<sup>1</sup>Department of Endocrinology, the Children's Hospital of Zhejiang University School of Medicine, No 3333 Binsheng Road, Hangzhou 310051, Zhejiang Province, China. <sup>2</sup>Department of Pediatrics, the People's Hospital of Zhuji, Shaoxing, Zhejiang Province, China.

# Received: 3 November 2021 Accepted: 10 June 2022 Published online: 11 July 2022

#### References

- Stepien KM, Ciara E, Jezela-Stanek A. Fucosidosis-Clinical Manifestation, Long-Term Outcomes, and Genetic Profile-Review and Case Series. Genes (Basel). 2022;11(11):1383.
- Wang L, et al. Fucosidosis in a Chinese boy: a case report and literature review. J Int Med Res. 2020;48:1–6. https://doi.org/10.1177/0300060520 911269.
- Kanitakis J, et al. Fucosidosis with angiokeratoma. Immunohistochemical & electronmicroscopic study of a new case and literature review. J Cutan Pathol. 2055;32:506–11.
- George S, Graham-Brown RA. Angiokeratoma corporis diffusum in fucosidosis. J R Soc Med. 1994;87:707.

- Kaur A, Dhaliwal AS, Raynes H, Naidich TP, Kaufman DM. Diagnosis and Supportive Management of Fucosidosis: A Case Report. Cureus. 2019;11: e6139. https://doi.org/10.7759/cureus.6139.
- Zhang X, et al. Identification of a novel homozygous loss-of-function mutation in FUCA1 gene causing severe fucosidosis: A case report. J Int Med Res. 2021;49:3000605211005975. https://doi.org/10.1177/03000 605211005975.
- Willems PJ, et al. Fucosidosis revisited: a review of 77 patients. Am J Med Genet. 1991;38:111–31. https://doi.org/10.1002/ajmg.1320380125.
- Gautschi M, et al. Late diagnosis of fucosidosis in a child with progressive fixed dystonia, bilateral pallidal lesions and red spots on the skin. Eur J Paediatr Neurol. 2014;18:516–9. https://doi.org/10.1016/j.ejpn.2014.02. 005.
- Muthusamy K, et al. Siblings with fucosidosis. J. Pediatr Neurosci. 2014;9:156–8. https://doi.org/10.4103/1817-1745.139331.
- Oner AY, Cansu A, Akpek S, Serdaroglu A. Fucosidosis: MRI and MRS findings. Pediatr Radiol. 2007;37:1050–2. https://doi.org/10.1007/ s00247-007-0572-4.
- Mamourian AC, Hopkin JR, Chawla S, Poptani H. Characteristic MR spectroscopy in fucosidosis: in vitro investigation. Pediatr Radiol. 2010;40:1446–9. https://doi.org/10.1007/s00247-010-1593-y.
- Malatt C, Koning JL, Naheedy J. Skeletal and Brain Abnormalities in Fucosidosis, a Rare Lysosomal Storage Disorder. J Radiol Case Rep. 2015;9:30–8. https://doi.org/10.3941/jrcr.v9i5.2149.
- Jiang M, et al. Brain abnormalities in fucosidosis: transplantation or supportive therapy? Metab Brain Dis. 2017;32:317–20. https://doi.org/10. 1007/s11011-017-9968-5.
- Naumchik BM, et al. The role of hematopoietic cell transplant in the glycoprotein diseases. Cells. 2020;9(6):1411. https://doi.org/10.3390/cells 9061411.
- Kondagari GS, et al. The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis. Orphanet J Rare Dis. 2015;10:143. https://doi.org/10.1186/ s13023-015-0357-z.

#### **Publisher's note**

Springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

